Quick Answer
GYRE THERAPEUTICS, INC. reported Operating Income Loss of $11.49 million for the year ending 2025.
- GYRE THERAPEUTICS, INC. showed a decrease of -28.9% in Operating Income Loss from 2024 to 2025.
- This data is from GYRE THERAPEUTICS, INC.'s annual report (Form 10-K), filed with the SEC on March 13, 2026.
- XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2013: -$13.15 million | Q4 2013: -$13.31 million | Q1 2014: -$1.86 million | Q2 2014: -$2.21 million | Q3 2014: -$1.64 million | Q4 2014: -$1.80 million | Q1 2015: -$3.03 million | Q2 2015: -$2.20 million | Q3 2015: -$3.89 million | Q4 2015: -$4.68 million | Q1 2016: -$4.57 million | Q2 2016: -$4.92 million | Q3 2016: -$5.71 million | Q1 2017: -$4.17 million | Q2 2017: -$5.94 million | Q3 2017: -$5.88 million | Q1 2018: -$6.68 million | Q2 2018: -$7.11 million | Q3 2018: -$8.35 million | Q1 2019: -$15.71 million | Q2 2019: -$14.38 million | Q3 2019: -$13.20 million | Q1 2020: -$5.07 million | Q2 2020: -$17.36 million | Q3 2020: -$16.10 million | Q1 2021: -$22.44 million | Q2 2021: -$19.91 million | Q3 2021: -$25.23 million | Q1 2022: -$14.70 million | Q2 2022: $51.53 million | Q3 2022: -$5.17 million | Q1 2023: $6.66 million | Q2 2023: $4.97 million | Q3 2023: $12.76 million | Q1 2024: $8.07 million | Q2 2024: $3.19 million | Q3 2024: $4.23 million | Q1 2025: $2.27 million | Q2 2025: $2.17 million | Q3 2025: $6.93 million.
- Over the full 17 years of available data (2009 to 2025), GYRE THERAPEUTICS, INC.'s Operating Income Loss has grown by 128.5%.
- Historical annual values: Fiscal year 2025: $11.49 million | Fiscal year 2024: $16.16 million | Fiscal year 2023: -$67.23 million | Fiscal year 2022: $9.20 million | Fiscal year 2021: -$87.89 million | Fiscal year 2020: -$57.37 million | Fiscal year 2019: -$57.28 million | Fiscal year 2018: -$33.82 million | Fiscal year 2017: -$21.82 million | Fiscal year 2016: -$20.42 million | Fiscal year 2015: -$13.80 million | Fiscal year 2014: -$7.51 million | Fiscal year 2013: -$10.12 million | Fiscal year 2012: -$8.14 million | Fiscal year 2011: -$9.75 million | Fiscal year 2010: $13.12 million | Fiscal year 2009: -$40.33 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: